Market Overview

The Australia acute respiratory distress syndrome (ARDS) market size reached USD 39.56 Million in 2025, according to the latest report from IMARC Group. The market is projected to reach USD 88.52 Million by 2034, exhibiting a growth rate (CAGR) of 9.36% during 2026-2034.

Market growth is driven by rapid advancements in extracorporeal membrane oxygenation (ECMO) technology and mechanical ventilation systems, aggressive ICU capacity expansion supported by government healthcare infrastructure investments, and rising prevalence of chronic respiratory diseases amid an aging population, with heightened awareness of post-COVID lung damage further strengthening the Australia ARDS market share.

Request Sample Report (Including Graphs, Charts & Figures):
https://www.imarcgroup.com/australia-acute-respiratory-distress-syndrome-market/requestsample

How AI is Reshaping the Future of the Australia ARDS Market

The integration of artificial intelligence into Australia‘s critical care ecosystem is fundamentally transforming ARDS diagnosis, treatment, and patient monitoring.

AI-Integrated Respiratory Support Systems – The integration of AI and machine learning into respiratory support systems enhances treatment precision by analyzing large datasets from electronic health records and medical imaging to identify early ARDS signs, predict disease progression, and recommend personalized treatment protocols. AI-powered mechanical ventilation systems now deliver tailored respiratory support that adapts to individual patient lung mechanics, while advanced monitoring techniques such as electrical impedance tomography provide real-time imaging to optimize ventilator settings and minimize ventilator-induced lung injury.

AI-Powered Biomarker Platforms for Respiratory Disease – In August 2025, the Australian Government awarded $3 million to Diag‑Nose.io for developing RhinoMAP, an AI‑powered biomarker platform that monitors respiratory disease treatment response. The platform uses protein biomarkers from nasal fluid samples combined with patient‑reported data to deliver a real‑time picture of airway inflammation, addressing a critical gap where up to 50% of patients do not achieve adequate treatment response. “RhinoMAP is like a radar for the respiratory system,” said Eldin Rostom, CEO and Co‑Founder of Diag‑Nose.io. “It reveals whether inflammation is escalating, stable, or resolving to help clinicians course-correct or stay the path with confidence.”

AI-Enhanced Early Detection and Workflow Optimization – AI and machine learning algorithms are being deployed to detect early signs of patient deterioration, especially in those undergoing mechanical ventilation. These systems filter through clinical data to identify significant changes in patient conditions requiring immediate intervention. Additionally, AI is being used to automate patient trial eligibility screening and recruitment using existing hospital electronic datasets, accelerating clinical research in ARDS.

National AI Strategy and Government Support – The Australian Government is actively supporting AI adoption in healthcare through initiatives such as the Cooperative Research Centres Projects (CRC‑P) program, which funded the Diag‑Nose.io project. The total project value is $8.4 million, with contributions from Monash University, Mater Research, ENT Clinic Melbourne, and other partners. Australia‘s AI health models are increasingly being recognized as critical tools for improving diagnostic accuracy and treatment outcomes, though experts emphasize that these models are “only as good as the data they’re trained on”.

Australia ARDS Market Trends

Expansion of ICU Capacity and Healthcare Infrastructure Investment – The Australian government is actively strengthening healthcare infrastructure through sustained investments in intensive care unit capacity expansion and advanced respiratory care capabilities. In August 2024, Canberra Hospital commenced operations of its new Critical Services Building featuring an expanded 48‑bed ICU as part of a comprehensive hospital expansion project. The nine‑storey, 45,000‑square‑meter building represents Australia‘s first all‑electric hospital building. Government funding initiatives support the acquisition of advanced mechanical ventilators, ECMO devices, and sophisticated monitoring equipment.

Advancements in ECMO Technology and Mechanical Ventilation Systems – ECMO devices have evolved to provide life‑saving circulatory and respiratory support for critically ill patients with severe ARDS, now featuring enhanced portability, user‑friendly interfaces, and improved biocompatibility. In September 2024, Medtronic introduced the VitalFlow ECMO System, a flexible and modular platform designed to bridge the gap between bedside care and intra‑hospital transport, featuring a large, intuitive touchscreen that centralizes real‑time performance data.

Rising Prevalence of Respiratory Diseases – In 2022, an estimated 8.5 million (34%) Australians had chronic respiratory diseases, such as asthma and COPD. Approximately 2.8 million (11%) individuals had asthma, and 638,000 (2.5%) had COPD. The nation‘s aging population, specifically exposed to these conditions, has seen an accelerated rise in hospitalizations, creating sustained demand for advanced ARDS treatment.

Australia ARDS Market Summary

• Market Valuation: USD 39.56 Million (2025) → USD 88.52 Million (2034), CAGR 9.36%
• Respiratory Disease Burden: 8.5 million Australians (34%) have chronic respiratory diseases
• Treatment Modalities: Medication/drug class (vasoconstrictors, bronchodilators, corticosteroids, antibiotics, sedatives, paralytics, surfactants) and medical devices (mechanical ventilators, ECMO, inhaled nitric oxide delivery systems, diagnostic and monitoring devices)
• Cause of Lung Injury: Direct injury and indirect injury
• Severity: Mild, moderate, and severe
• End Users: Hospitals and intensive care units, specialty clinics
• Regions: Australian Capital Territory & New South Wales, Victoria & Tasmania, Queensland, Northern Territory & Southern Australia, Western Australia

Australia ARDS Market Growth Drivers

Continual Technological Advancements in ECMO and Ventilation – Rapid innovations in ECMO technology and mechanical ventilation systems are significantly propelling market growth. Modern ECMO systems feature enhanced portability, user‑friendly interfaces, and improved biocompatibility, reducing complications related to clotting and bleeding. Mechanical ventilation has become increasingly sophisticated, delivering tailored respiratory support that adapts to individual patient physiology. The integration of AI further enhances treatment precision by analyzing large datasets to identify early ARDS signs, predict disease progression, and recommend personalized treatment protocols.

Aggressive ICU Capacity Expansion and Infrastructure Investment – The Australian government‘s sustained investments in intensive care unit capacity expansion address growing demand for critical care services driven by an aging population, increased rates of chronic respiratory conditions, and heightened awareness of post‑COVID lung damage. These strategic investments support the acquisition of cutting‑edge medical technology and workforce development, including recruiting and training specialized intensive care physicians, respiratory therapists, and critical care nurses. Canberra Hospital’s new 48‑bed ICU exemplifies this infrastructure modernization.

Rising Respiratory Disease Prevalence and Post‑COVID Awareness – Australia is witnessing a significant surge in chronic respiratory ailments such as COPD, pneumonia, and severe influenza, which are among the major causes of ARDS. Long‑term complications post‑COVID‑19 have contributed substantially to the need for inclusive ARDS treatment. The nation‘s older population, specifically exposed to these conditions, has seen an accelerated rise in hospitalizations and an increased need for advanced respiratory treatment.

Government and Research Investment – The Australian Government’s $3 million CRC‑P grant to Diag‑Nose.io for AI‑powered respiratory disease monitoring, along with Wesley Research Institute‘s 2025 research grant rounds supporting ARDS mechanism studies, demonstrates strong public and private commitment to ARDS innovation. Queensland researchers launched the first human study exploring Biofluid‑Induced Lung Injury, a previously overlooked mechanism that may explain how lung injury spreads in ARDS, funded by Wesley Research Institute.

Australia ARDS Market Segments

Breakup by Treatment Modality

• Medication/Drug Class (Vasoconstrictors, Bronchodilators, Corticosteroids and Antibiotics, Sedatives and Paralytics, Surfactants, Others)
• Medical Device (Mechanical Ventilators, ECMO and Artificial Lung Systems, Inhaled Nitric Oxide Delivery Systems, Diagnostic and Monitoring Devices, Others)

Breakup by Cause of Lung Injury

• Direct Injury
• Indirect Injury

Breakup by Severity

• Mild
• Moderate
• Severe

Breakup by End User

• Hospitals and Intensive Care Units
• Specialty Clinics
• Others

Breakup by Region

• Australian Capital Territory & New South Wales
• Victoria & Tasmania
• Queensland
• Northern Territory & Southern Australia
• Western Australia

Competitive Landscape of the Australia ARDS Market

The Australia ARDS market features a dynamic mix of global medical device giants, pharmaceutical companies, and specialized respiratory care providers.

Major players include Medtronic (VitalFlow ECMO System), Gilead Sciences, Pfizer, Silence Therapeutics, Terumo, Getinge, Livanova, Fresenius, and Nipro. Medtronic‘s VitalFlow ECMO System, introduced in September 2024, represents a significant advancement in ECMO technology with enhanced portability and real‑time performance data centralization.

Emerging AI‑focused companies such as Diag‑Nose.io are contributing to the digital transformation of respiratory disease monitoring with AI‑powered biomarker platforms.

Research Institutions – The Critical Care Research Group (CCRG) , Wesley Research Institute, Monash University, Mater Research, and the University of Queensland are actively engaged in ARDS pathophysiology research and clinical trials.

Competition is centered on technological innovation, AI integration, device portability, biocompatibility, and distribution reach across Australian hospitals and ICUs.

Latest Recent News & Development in the Australia ARDS Market

February 2026: Wesley Research Institute launched a laboratory investigation into how inflammatory lung fluid from ARDS patients may drive the spread of lung injury, aiming to identify treatment approaches that prevent disease progression.

January 2026: Metro North Health announced Dr Gianluigi Li Bassi‘s 2025 Clinician Research Fellowship program focused on advancing ARDS pathophysiology understanding, enhancing treatment, and reducing iatrogenic harm. The research will develop an automated system for patient trial eligibility screening using existing hospital electronic datasets.

December 2025: Queensland researchers launched the first human study to explore Biofluid‑Induced Lung Injury (BILI), a previously overlooked mechanism explaining how lung injury spreads in ARDS, funded by Wesley Research Institute. The pilot study will collect blood and lung fluid samples from ARDS patients within 48 hours of diagnosis.

August 2025: The Australian Government awarded $3 million to Diag‑Nose.io for developing RhinoMAP, an AI‑powered biomarker platform for respiratory disease, under the CRC‑P program. The total project value is $8.4 million.

September 2024: Medtronic introduced the VitalFlow ECMO System in Australia, a flexible and modular platform designed to bridge the gap between bedside care and intra‑hospital transport.

August 2024: Canberra Hospital commenced operations of its new Critical Services Building featuring an expanded 48‑bed ICU, representing Australia‘s first all‑electric hospital building.

Browse Full Report with TOC & List of Figures:
https://www.imarcgroup.com/australia-acute-respiratory-distress-syndrome-market

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest‑value opportunities, address their most critical challenges, and transform their businesses.

IMARC‘s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for medical devices, diagnostics, healthcare, and novel processing methods are at the top of the company’s expertise.

Contact Us

IMARC Group
134 N 4th St., Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com
Tel No: (D) +91 120 433 0800
United States: +1-631-791-1145